Business
BioVie's Lead Drug Candidate Aims To Treat Neurodegenerative Disease By Targeting Inflammation
CARSON CITY, NV / ACCESSWIRE / September 20, 2023 / As researchers continue to hunt for better treatments for neurodegenerative disease, one of the biggest
About this update from Biovie Inc.
[{"type":"text","content":"CARSON CITY, NV / ACCESSWIRE / September 20, 2023 / As researchers continue to hunt for better treatments for neurodegenerative disease, one of the biggest breakthroughs in decades has been the realization that chronic inflammation may be playing a key role in the onset and progression of debilitating diseases like Alzheimer's and Parkinson's disease. That's led biotechs like BioVie (NASDAQ:BIVI) to turn the focus to treatments that block or alter inflammation as a way to also stop the neurodegeneration causing the progressively worsening symptoms. NE3107, BioVie's lead drug candidate that modulates inflammation is now in late-stage clinical trials for Alzheimer's and Parkinson's disease. Mounting Evidence For The Role Of Chronic Inflammation In Neurodegenerative DiseasesOne of the first hints that inflammation played a role in neurodegenerative disease was the emergence of several studies showing that people who take \"anti-TNF\" drugs such as Enbrel and Humira were up to 50% less likely to develop Alzheimer's disease later in life.Since then, researchers have been digging into exactly why inflammation - especially chronic inflammation - increases a person's risk of developing Alzheimer's, Parkinson's and other neurodegenerative diseases.Inflammation is a natural outcome when your immune cells fight off pathogens or repair damage. But if the inflammation persists and becomes chronic, it also causes progressively worsening damage to the body, which can show up as Alzheimer's, Parkinson's, Rheumatoid Arthritis and other conditions.In neurodegenerative diseases, chronic brain inflammation causes neuronal cell death and increasing toxicity that can weaken the connections between synapses in the brain. It's now believed that inflammation is the central mechanism behind the plaque buildup and tau tangling thought to trigger Alzheimer's disease. In Parkinson's disease, studies have found a strong link between inflammation and the associated insulin resistance as a critical driver of the neurodegenerative disease.NE3107 Targets Multiple Sources Of Inflammation To Reduce The Inflammatory CascadeBioVie's lead drug candidate, NE3107 is an oral drug that's designed to selectively block inflammatory signaling pathways to reduce inflammation and enhance insulin sensitivity without blocking the homeostatic functions of those signaling pathway...